Por: RTTNews Health September 13, 2023
Alnylam Pharmaceuticals, Inc. () said NASDAQ has halted trading of the company's common stock on Wednesday as the FDA Cardiovascular and Renal Drugs Advisory Committee is meeting to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis.Patisiran is the established name for ONPATTRO, which is approved by the... + full article
The Boston Globe USA Business July 24, 2023
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as $2.8 billion, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.Roche will pay... + más
Alnylam signs $2.8 billion deal with Roche to advance Cambridge biotech’s injection for high blood pressure | The Boston Globe
Alnylam’s experimental Alzheimer’s drug shows benefits in patients for six months | The Boston Globe
Alnylam Pharmaceuticals will receive $310 million in cash from the Swiss drug giant Roche Holding AG and be eligible for as much as $2.5 billion more in a deal to jointly develop and market the Cambridge biotech’s novel potential treatment for high blood pressure.The firms... + más
Alnylam halts work on eye drug, citing new US law over pricing | The Boston Globe
The Boston Globe USA Business July 17, 2023
Alzheimer’s patients who received a single dose of an experimental gene-silencing treatment from Alnylam Pharmaceuticals showed benefits for six months in a small study, the Cambridge biotech said Monday.Alnylam reported in April that recipients of the medicine experienced... + más
Alnylam deploys gene-silencing in early study aimed at subduing Alzheimer’s | The Boston Globe
The Boston Globe USA Business April 26, 2023
Cambridge scientists are deploying a novel gene-silencing technology used against ultra-rare diseases in a new effort to subdue Alzheimer’s, the memory-raving disorder that afflicts tens of millions of people worldwide.In findings reported Wednesday afternoon, Alnylam... + más
Reimagining Alzheimer’s (Part 8): APOE4 Removal Reduces Symptoms Of Alzheimer’s Disease | Forbes
Orlando Sentinel USA Sports March 29, 2023
Lake Brantley 9, Seminole 6 (8 inn.) Buzz: Jackson Golden went 2-for-5 with 2 home runs and 6 RBI for Lake Brantley. Ben Colley had a home run. Bryce Carter had 2 hits for Seminole. Mount Dora Christian Academy 10, Oak Hall (Gainesville) 4 Buzz: Collin Priest went 5-for-5 with a... + más
NFL Playoff Scenarios | ABC News
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
Orlando Sentinel USA Sports March 25, 2023
Orangewood Christian 11, The Master’s Academy 1 Buzz: Austin Waring threw 5 innings of 1-run ball (0 earned runs) while allowing 4 hits and striking out 8 for Orangewood Christian. He lowered his season ERA to 0.78. Aiden McKee went 3-for-3 with a double, a walk, an RBI and a... + más
The Boston Globe USA Business October 27, 2022
Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.Alnylam will not begin a planned late-stage trial of its drug... + más
ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook | RTTNews
Halted Stocks | Forbes
About iurex | Privacy Policy | Disclaimer |